Paratek Pharmaceuticals (NASDAQ:PRTK) PT Set at $27.00 by HC Wainwright

Paratek Pharmaceuticals (NASDAQ:PRTK) has been given a $27.00 price target by equities research analysts at HC Wainwright in a note issued to investors on Monday, TipRanks reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 404.67% from the company’s current price.

PRTK has been the topic of a number of other research reports. ValuEngine upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 price target for the company in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $18.79.

Paratek Pharmaceuticals stock traded up $0.31 during midday trading on Monday, reaching $5.35. 996,699 shares of the stock traded hands, compared to its average volume of 335,033. The company has a current ratio of 12.17, a quick ratio of 11.83 and a debt-to-equity ratio of 14.48. The firm has a fifty day moving average price of $3.84 and a two-hundred day moving average price of $4.67. The firm has a market cap of $149.66 million, a price-to-earnings ratio of -1.50 and a beta of 1.74. Paratek Pharmaceuticals has a fifty-two week low of $2.87 and a fifty-two week high of $12.20.



Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. The company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $1.86 million. Analysts anticipate that Paratek Pharmaceuticals will post -4.37 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Paratek Pharmaceuticals by 45.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,602,747 shares of the specialty pharmaceutical company’s stock worth $6,394,000 after buying an additional 501,177 shares during the period. Roumell Asset Management LLC grew its position in Paratek Pharmaceuticals by 3.2% in the second quarter. Roumell Asset Management LLC now owns 678,795 shares of the specialty pharmaceutical company’s stock valued at $2,708,000 after purchasing an additional 21,099 shares in the last quarter. General American Investors Co. Inc. increased its stake in Paratek Pharmaceuticals by 1.1% in the 2nd quarter. General American Investors Co. Inc. now owns 470,185 shares of the specialty pharmaceutical company’s stock valued at $1,876,000 after buying an additional 5,200 shares during the last quarter. Northern Trust Corp lifted its position in Paratek Pharmaceuticals by 1.1% during the 2nd quarter. Northern Trust Corp now owns 414,364 shares of the specialty pharmaceutical company’s stock worth $1,653,000 after buying an additional 4,517 shares in the last quarter. Finally, Water Island Capital LLC boosted its stake in shares of Paratek Pharmaceuticals by 15.1% during the 1st quarter. Water Island Capital LLC now owns 366,648 shares of the specialty pharmaceutical company’s stock worth $1,965,000 after buying an additional 48,130 shares during the last quarter. Institutional investors own 71.34% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Recommended Story: What is meant by a buy rating?

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.